The world’s first injectable medication to reduce the risk of acquiring HIV has been approved by the Food and Drug Administration (FDA), the agency announced Monday (December 20).

The injectable drug – called Apretude or its generic name, “cabotegravir extended-release injectable suspension” – provides an alternative to daily pills for HIV prevention, such as Truvada and Descovy. These pills are up to 99 percent effective at preventing the sexual transmission of HIV, but must be taken every day to be that effective, according to the Centers for Disease Control and Prevention (CDC).

By contrast, to start Apretude, people initially receive two shots, spaced one month apart, and then they receive an injection every two months thereafter, according to the FDA statement.